| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Basic Science Investigations |
1 Division of Radiological Chemistry, Department of Radiology, University Hospital Basel, Basel, Switzerland
2 Department of Pharmacology and Toxicology, Otto-von-Guericke University, Magdeburg, Germany
Auger electron–emitting radionuclides have potential for the therapy of small-size cancers because of their high level of cytotoxicity, low-energy, high linear energy transfer, and short-range biologic effectiveness. Biologic effects are critically dependent on the subcellular (and even subnuclear) localization of these radionuclides. Our goals were the design, synthesis, and in vitro preclinical assessment of new trifunctional conjugates of somatostatin that should aim at the nucleus and, therefore, ensure a longer retention time in the cell, a close approximation to the DNA, and the success of Auger electron emitters in targeted radionuclide therapy as well as also improve other targeted therapy strategies. Methods: Three trifunctional derivatives of [(1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid)0,Tyr3]octreotide (DOTA-TOC) bearing the nuclear localization signal (NLS) (of simian virus 40 large-T antigen) PKKKRKV in 3 different positions relative to the somatostatin analog sequence were synthesized using solid and solution phase peptide synthesis. These compounds together with DOTA-TOC and DOTA-NLS derivatives were labeled with 111In and tested for binding affinity, internalization, externalization, and nuclei localization on AR4-2J cells and on human embryonic cells stably transfected with sst2A. Results: The two N-terminal derivatives preserved the sstr2A binding affinity. Their rate of internalization in all tested sstr-expressing cell lines was always superior for the trifunctional derivatives in comparison with the parent compound. A 6-fold increase in cellular retention from the total internalized activity and a 45-fold higher accumulation in the cell nuclei were found for one of the N-terminally modified compounds compared with [111In]-DOTA-TOC. The C-terminal conjugate was inferior in all tests compared with the parent compound. Conclusion: These encouraging results support our hypothesis that an additional NLS sequence to the DOTA-TOC could not only provide a better carrier for Auger electron–emitting radionuclides but also ensure a longer radioactivity retention time in the tumor cell.
Key Words: nuclear localization signal • Auger electron emitter • nuclear uptake • 111In
Related articles in JNM:
This article has been cited by other articles:
|
|
 |
|
  K. E. Bailey, D. L. Costantini, Z. Cai, D. A. Scollard, Z. Chen, R. M. Reilly, and K. A. Vallis Epidermal Growth Factor Receptor Inhibition Modulates the Nuclear Localization and Cytotoxicity of the Auger Electron Emitting Radiopharmaceutical 111In-DTPA Human Epidermal Growth Factor J. Nucl. Med., September 1, 2007; 48(9): 1562 - 1570. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. L. Costantini, C. Chan, Z. Cai, K. A. Vallis, and R. M. Reilly 111In-Labeled Trastuzumab (Herceptin) Modified with Nuclear Localization Sequences (NLS): An Auger Electron-Emitting Radiotherapeutic Agent for HER2/neu-Amplified Breast Cancer J. Nucl. Med., August 1, 2007; 48(8): 1357 - 1368. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Ginj, H. Zhang, B. Waser, R. Cescato, D. Wild, X. Wang, J. Erchegyi, J. Rivier, H. R. Macke, and J. C. Reubi Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors PNAS, October 31, 2006; 103(44): 16436 - 16441. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. A. Boswell and M. W. Brechbiel Auger Electrons: Lethal, Low Energy, and Coming Soon to a Tumor Cell Nucleus Near You J. Nucl. Med., December 1, 2005; 46(12): 1946 - 1947. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |
